NCT04699877View on ClinicalTrials.gov

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions

Renal ImpairedGilteritinibNormal Renal FunctionPharmacokinetics of ASP2215

Interventions

DRUG

Gilteritinib

Oral

Trial Locations (4)

1000

Site BG35901, Sofia

32809

Orlando Clinical Research Center, Orlando

92780

Orange County Research Institute, Tustin

92844

National Institute of Clinical Research, Garden Grove

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04699877 - A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function | Biotech Hunter | Biotech Hunter